|
Amag Pharmaceuticals News is an EIN News Service for pharmaceuticals professionals. Constantly updated news and information about pharmaceuticals.
Latest Amag Pharmaceuticals News
- AMAG Pharmaceuticals, Inc.-Detailed Product Pipeline - research report released 3 Nov 2009 03:32 GMT
... AMAG Pharmaceuticals, Inc.-Detailed Product Pipeline - a new market ... details consist of complete descriptions, therapeutic indication, drug class, mechanism of action and clinical trial ...
- BioTrends Releases Three Publications - TreatmentTrends(R): US Nephrology, TreatmentTrends(R): Renal 5 Nov 2009 15:51 GMT
... time in the renal anemia market. Findings from Amgen's TREAT study were released and AMAG Pharmaceuticals launched their new IV iron product, Feraheme. TREAT results were disappointing -- the study ...
- BioTrends Releases Three Publications - TreatmentTrends(R): US Nephrology, TreatmentTrends(R): Renal Dietitians, and TreatmentTrends(R): Anemia Managers - Highlighting Market Trends for Renal Anemia, 5 Nov 2009 15:51 GMT
... time in the renal anemia market. Findings from Amgen's TREAT study were released and AMAG Pharmaceuticals launched their new IV iron product, Feraheme. TREAT results were disappointing -- the study ...
- BioTrends Releases Three Publications - TreatmentTrends(R): US Nephrology, TreatmentTrends(R): Renal Dietitians, and Tre 5 Nov 2009 15:53 GMT
... time in the renal anemia market. Findings from Amgen's TREAT study were released and AMAG Pharmaceuticals launched their new IV iron product, Feraheme. TREAT results were disappointing -- the study ...
- BioTrends Releases Three Publications - TreatmentTrends(R): US Nephrology, TreatmentTrends(R): Renal Dietitians, and TreatmentTrends(R): Anemia Managers - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Seconda 5 Nov 2009 16:11 GMT
... time in the renal anemia market. Findings from Amgen's TREAT study were released and AMAG Pharmaceuticals launched their new IV iron product, Feraheme. TREAT results were disappointing -- the study ...
- Comorbidities Determine Effects of Raising Hemoglobin 3 Nov 2009 22:52 GMT
... Explain to interested patients that this was a post hoc ... NABI, Gilead, , Kureha, Affymax, Acologix, Roche, Pharmasset, Merck, and AstraZeneca, and receiving honoraria from ... America, GlaxoSmithKline, Genzyme, Abbott, Amgen, OBI, and AMAG. American Society of Nephrology Source reference: Szczech ...
- AMAG Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2009 29 Oct 2009 12:11 GMT
... LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: ), a biopharmaceutical company focused ... received approval from the U.S. Food and Drug Administration to market Feraheme for the treatment ...
- Updates for Curis (NASDAQ:CRIS), AMAG (NASDAQ:AMAG), King (NYSE:KG), Sucampo (NASDAQ:SCMP) 31 Oct 2009 10:30 GMT
... Updates for Curis (NASDAQ:CRIS), AMAG (NASDAQ:AMAG), King (NYSE:KG), Sucampo (NASDAQ:SCMP) BioMedReports.Com, the ... quarter ended September 30, 2009. On 10/29/09, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a biopharmaceutical company focused on ...
- BiomedReports: News and FDA Updates for Curis (NASDAQ:CRIS), AMAG (NASDAQ:AMAG), King (NYSE:KG), Sucampo (NASDAQ:SCMP) 30 Oct 2009 15:00 GMT
... BioMedReports.Com On 29/10/09, Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted ... quarter ended September 30, 2009. On 29/10/09, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a biopharmaceutical company focused on ...
- AMAG Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2009 (BIZ) 29 Oct 2009 12:10 GMT
... -- The Company commenced the U.S. commercial launch of Feraheme(TM) (ferumoxytol) ... third quarter, years of hard work by AMAG employees culminated in the launch of Feraheme, ... the transformation of AMAG into a commercial biopharmaceutical company," commented Brian J.G. Pereira, M.D., President ...
- HCV Changes Dialysis Treatment Needs 30 Oct 2009 20:15 GMT
... MD, of the Arbor Research Collaborative for Health in Ann Arbor, Mich. This is a ... and Genzyme. Goodkin reported relationships with Affymax, AMAG Pharmaceuticals, Amgen, FibroGen, Keryx, Seattle Life Sciences, Xenon ...
- No Clinical Benefit for ESA in Anemic Patients with Diabetes, CKD 31 Oct 2009 01:53 GMT
... president Thomas Coffman, MD, of Duke University Medical Center said the study provided "very useful ... Medtronic, Novartis, Roche, sanofi-aventis, Servier, and VIA Pharmaceuticals, and grant support from Amgen, Baxter, Celladon, ... Pfizer, Scios, GlaxoSmithKline, Johnson & Johnson, Watson, AMAG Pharmaceuticals, and Abbott. ...
- AMAG Pharmaceuticals Down 8.6% Since SmarTrend's Sell Recommendation 31 Oct 2009 12:41 GMT
... ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Pharmaceutical Industry Today
|
a digital news provider
bloomberg.com:
healthday.com:
msnbc.msn.com: